The next generation of ultrasound contrast agents
How it works
Tide Microfluidics’ novel platform technology allows for the creation of monodisperse microparticles. Our unique platform shows a robust method for the production of microbubbles or microdroplets of highly controlled size with a choice of size in the micron range and a narrow size distribution.
The demand for affordable and efficient healthcare is increasing throughout the world. A key tool to meet this challenge is the effective use of diagnostic imaging. The use of early stage and targeted imaging ensures a better diagnosis for the patient and lower long-term treatment costs for healthcare providers.
Through the use of our proprietary technology we are able to offer low volume production of specially designed and engineered microbubbles that can be used. We are able to create sample volumes or low batch production using our latest generation platform system.
To meet the demand for more accurate and efficient imaging diagnostics the use of contrast agents is common practice. We aim to use our platform technology to enable the production of the next generation of contrast agents
A next generation use for micobubbles is as a delivery method for medicines, commonly referred to as target drug delivery. Ultimately this leads to a next generation in medicine where treatments are personalised and the patient is treated as an individual, not the disease.
A closer look
Tide Microfluidics is proud to announce that in collaboration with DEMCON we have been awarded an EFRO R&D samenwerkingsprojecten (MIT) by OP Oost for “Mobiel Dispersieplatform voor Microbelletjes” – MeDIuM. In this project we are working to create a bedside...
Due to Tide’s continued growth, we have moved to larger office and laboratory facilities. These premises are situated on the Business and Science park in Enschede at Capitool 41, 7521 PL Enschede.
We will be presenting at the 2016 HealthTech Summit in Lausanne between 21st and 22nd June.